Search

Displaying results 4031 - 4040 of 4238 in total
  1. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  2. Drug

    SAR443122

    go.drugbank.com/drugs/DB16492
    Investigational

    SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally...

  3. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib wa...

  4. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies.

  5. Drug

    Umbilical Cord Blood Hematopoietic Stem Cells

    go.drugbank.com/drugs/DB15723
    Investigational

    Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels

  6. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who have had exposure to pico...

  7. Drug

    Cathinone

    go.drugbank.com/drugs/DB01560
    ExperimentalIllicit

    Internationally, cathinone is categorized as a Schedule I drug. Cathinone was added to the Controlled Substances Act's Schedule I in 1993 in compliance with international laws.

  8. Drug

    MX6

    go.drugbank.com/drugs/DB05789
    Experimental

    (1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as

  9. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which express high levels of CD-10* or TOP** peptidases, such as

  10. Drug

    AN0128

    go.drugbank.com/drugs/DB05054
    Investigational

    AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.